Capital World Investors Takes Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Capital World Investors bought a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 205,100 shares of the company's stock, valued at approximately $9,291,000. Capital World Investors owned approximately 0.46% of Apogee Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Marshall Wace LLP raised its stake in shares of Apogee Therapeutics by 1,963.9% in the 4th quarter. Marshall Wace LLP now owns 75,849 shares of the company's stock valued at $3,436,000 after acquiring an additional 72,174 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in Apogee Therapeutics by 40.3% during the fourth quarter. Affinity Asset Advisors LLC now owns 931,728 shares of the company's stock valued at $42,207,000 after purchasing an additional 267,530 shares during the last quarter. Jump Financial LLC bought a new position in shares of Apogee Therapeutics in the fourth quarter valued at approximately $945,000. XTX Topco Ltd acquired a new stake in shares of Apogee Therapeutics in the fourth quarter worth $288,000. Finally, Barclays PLC boosted its holdings in shares of Apogee Therapeutics by 30.6% during the 4th quarter. Barclays PLC now owns 476,760 shares of the company's stock worth $21,597,000 after buying an additional 111,714 shares during the period. Institutional investors and hedge funds own 79.04% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on APGE shares. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Citigroup initiated coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $95.00 price objective on the stock. Finally, Wedbush restated an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $92.17.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE traded down $0.20 during mid-day trading on Friday, hitting $36.85. The company had a trading volume of 578,730 shares, compared to its average volume of 511,568. Apogee Therapeutics, Inc. has a 12 month low of $26.20 and a 12 month high of $63.50. The firm has a market cap of $1.66 billion, a P/E ratio of -15.23 and a beta of 1.72. The business's 50-day simple moving average is $35.11 and its 200-day simple moving average is $42.94.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). As a group, sell-side analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 3,520 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80. Following the completion of the transaction, the insider now owns 252,623 shares in the company, valued at $10,279,229.87. This trade represents a 1.37 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief executive officer now owns 1,292,987 shares in the company, valued at $38,983,558.05. This trade represents a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 33,970 shares of company stock valued at $1,241,701. Company insiders own 36.10% of the company's stock.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.